loading
Schlusskurs vom Vortag:
$14.72
Offen:
$14.56
24-Stunden-Volumen:
829.52K
Relative Volume:
0.34
Marktkapitalisierung:
$1.61B
Einnahmen:
$59.61M
Nettoeinkommen (Verlust:
$-262.14M
KGV:
-3.727
EPS:
-3.92
Netto-Cashflow:
$-247.49M
1W Leistung:
+12.30%
1M Leistung:
-14.61%
6M Leistung:
+66.97%
1J Leistung:
+70.08%
1-Tages-Spanne:
Value
$14.21
$14.77
1-Wochen-Bereich:
Value
$12.79
$15.02
52-Wochen-Spanne:
Value
$6.99
$17.75

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Name
Firmenname
Arcutis Biotherapeutics Inc
Name
Telefon
805-418-5006
Name
Adresse
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Name
Mitarbeiter
342
Name
Twitter
@ArcutisBio
Name
Nächster Verdiensttermin
2024-12-06
Name
Neueste SEC-Einreichungen
Name
ARQT's Discussions on Twitter

Vergleichen Sie ARQT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ARQT
Arcutis Biotherapeutics Inc
14.61 1.61B 59.61M -262.14M -247.49M -3.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-30 Eingeleitet H.C. Wainwright Buy
2024-08-28 Eingeleitet Jefferies Buy
2024-01-03 Hochstufung Mizuho Neutral → Buy
2023-10-26 Herabstufung Mizuho Buy → Neutral
2023-10-13 Herabstufung Goldman Buy → Neutral
2022-09-07 Eingeleitet Needham Buy
2022-03-17 Eingeleitet Goldman Buy
2021-06-30 Eingeleitet Mizuho Buy
2021-05-27 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-11-09 Hochstufung Goldman Neutral → Buy
2020-10-08 Eingeleitet Truist Buy
2020-02-25 Eingeleitet Cantor Fitzgerald Overweight
2020-02-25 Eingeleitet Cowen Outperform
2020-02-25 Eingeleitet Goldman Neutral
2020-02-25 Eingeleitet Guggenheim Buy
Alle ansehen

Arcutis Biotherapeutics Inc Aktie (ARQT) Neueste Nachrichten

pulisher
Apr 24, 2025

Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year? - MSN

Apr 24, 2025
pulisher
Apr 20, 2025

Learn to Evaluate (ARQT) using the Charts - news.stocktradersdaily.com

Apr 20, 2025
pulisher
Apr 19, 2025

Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets - Seeking Alpha

Apr 19, 2025
pulisher
Apr 18, 2025

Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market - GlobeNewswire Inc.

Apr 18, 2025
pulisher
Apr 17, 2025

Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025 - The Manila Times

Apr 17, 2025
pulisher
Apr 17, 2025

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): Is Breakeven Near? - simplywall.st

Apr 17, 2025
pulisher
Apr 11, 2025

Arcutis Biotherapeutics Appoints New Chief Financial Officer - MSN

Apr 11, 2025
pulisher
Apr 11, 2025

Arcutis Announces Chief Financial Officer Transition | ARQT Stoc - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Arcutis Biotherapeutics (ARQT) Announces CFO Transition - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Arcutis Biotherapeutics (ARQT) Announces Transition in CFO Role - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Arcutis Names New Chief Financial Officer - Contract Pharma

Apr 11, 2025
pulisher
Apr 11, 2025

Arcutis CFO David Topper retires, Latha Vairavan steps in By Investing.com - Investing.com India

Apr 11, 2025
pulisher
Apr 11, 2025

Arcutis Announces Chief Financial Officer Transition - BioSpace

Apr 11, 2025
pulisher
Apr 10, 2025

Arcutis Biotherapeutics Names New Chief Financial Officer - marketscreener.com

Apr 10, 2025
pulisher
Apr 10, 2025

Arcutis CFO David Topper retires, Latha Vairavan steps in - Investing.com Australia

Apr 10, 2025
pulisher
Apr 10, 2025

Psoriasis Pipeline Analysis and Clinical Trials Assessment, - openPR.com

Apr 10, 2025
pulisher
Apr 08, 2025

Arcutis at Needham Conference: Strategic Growth in Dermatology By Investing.com - Investing.com Canada

Apr 08, 2025
pulisher
Apr 04, 2025

Arcutis Biotherapeutics: Zoryve's Growth Impresses, But Valuation Is A Concern (Rating Upgrade) - Seeking Alpha

Apr 04, 2025
pulisher
Apr 04, 2025

Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last? - MSN

Apr 04, 2025
pulisher
Apr 04, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 04, 2025
pulisher
Apr 04, 2025

Arcutis Strengthens Team with Strategic Stock Grants to 5 Key New Hires - Stock Titan

Apr 04, 2025
pulisher
Apr 04, 2025

(ARQT) Trading Report - news.stocktradersdaily.com

Apr 04, 2025
pulisher
Apr 03, 2025

Arcutis stock holds buy rating, $19 target amid patent case By Investing.com - Investing.com Australia

Apr 03, 2025
pulisher
Apr 03, 2025

Arcutis Biotherapeutics director sells $151,236 in stock By Investing.com - Investing.com South Africa

Apr 03, 2025
pulisher
Apr 03, 2025

Arcutis Biotherapeutics director sells $151,236 in stock - Investing.com India

Apr 03, 2025
pulisher
Apr 03, 2025

Recent Insider Transactions at Arcutis Biotherapeutics - TradingView

Apr 03, 2025
pulisher
Apr 03, 2025

Demystifying Arcutis Biotherapeutics: Insights From 9 Analyst Reviews - Benzinga

Apr 03, 2025
pulisher
Apr 03, 2025

Arcutis stock holds buy rating, $19 target amid patent case - Investing.com

Apr 03, 2025
pulisher
Apr 03, 2025

Why Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday? - Yahoo Finance

Apr 03, 2025
pulisher
Apr 03, 2025

Arcutis Biotherapeutics (ARQT) Shares Rise Amid Patent Lawsuit P - GuruFocus

Apr 03, 2025
pulisher
Apr 02, 2025

Arcutis stock rises following litigation stay By Investing.com - Investing.com Canada

Apr 02, 2025
pulisher
Apr 02, 2025

Arcutis and Padagis agree to stay patent litigation By Investing.com - Investing.com South Africa

Apr 02, 2025
pulisher
Apr 02, 2025

Arcutis And Padagis Agree To Stay Patent Lawsuit - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Arcutis stock gains after pausing patent suit (ARQT:NASDAQ) - Seeking Alpha

Apr 02, 2025
pulisher
Apr 02, 2025

Arcutis rises after halting patent dispute with Padagis - TradingView

Apr 02, 2025
pulisher
Apr 02, 2025

Arcutis Agrees to Stay Patent Lawsuit Against Padagis - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Arcutis and Padagis Agree to Stay Patent Lawsuit - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

Arcutis and Padagis agree to stay patent litigation - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Strategic Win: Arcutis Secures Extended Patent Protection for ZORYVE Until 2037 - Stock Titan

Apr 02, 2025
pulisher
Apr 02, 2025

Arcutis: An Agent of Patient-Centric Transformation - Technology Magazine

Apr 02, 2025
pulisher
Mar 31, 2025

Seborrhoeic Dermatitis Market Growth to Accelerate in Forecast - openPR.com

Mar 31, 2025

Finanzdaten der Arcutis Biotherapeutics Inc-Aktie (ARQT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Kapitalisierung:     |  Volumen (24h):